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Introduction: We compared the economic impacts of linezolid and vancomycin for the treatment of hospitalized
patients with methicillin-resistant Staphylococcus aureus (MRSA)–confirmed nosocomial pneumonia.
Methods: We used a 4-week decision tree model incorporating published data and expert opinion on clinical
parameters, resource use and costs (in 2012 US dollars), such as efficacy, mortality, serious adverse events, treatment
duration and length of hospital stay. The results presented are from a US payer perspective. The base case first-line
treatment duration for patients with MRSA-confirmed nosocomial pneumonia was 10 days. Clinical treatment
success (used for the cost-effectiveness ratio) and failure due to lack of efficacy, serious adverse events or mortality
were possible clinical outcomes that could impact costs. Cost of treatment and incremental cost-effectiveness per
successfully treated patient were calculated for linezolid versus vancomycin. Univariate (one-way) and probabilistic
sensitivity analyses were conducted.
Results: The model allowed us to calculate the total base case inpatient costs as $46,168 (linezolid) and $46,992
(vancomycin). The incremental cost-effectiveness ratio favored linezolid (versus vancomycin), with lower costs
($824 less) and greater efficacy (+2.7% absolute difference in the proportion of patients successfully treated for
MRSA nosocomial pneumonia). Approximately 80% of the total treatment costs were attributed to hospital stay
(primarily in the intensive care unit). The results of our probabilistic sensitivity analysis indicated that linezolid is the
cost-effective alternative under varying willingness to pay thresholds.
Conclusion: These model results show that linezolid has a favorable incremental cost-effectiveness ratio compared
to vancomycin for MRSA-confirmed nosocomial pneumonia, largely attributable to the higher clinical trial response
rate of patients treated with linezolid. The higher drug acquisition cost of linezolid was offset by lower treatment
failure–related costs and fewer days of hospitalization.Introduction
Nosocomial pneumonia (NP) has been reported to be
the second most frequent hospital-acquired infection in
the United States [1]. Methicillin-resistant Staphylococcus
aureus (MRSA) is responsible for a large number of cases
of health-care–associated pneumonia, hospital-acquired
pneumonia and ventilator-associated pneumonia [2,3]. A* Correspondence: jstephens@pharmerit.com
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coccus aureus isolates that were methicillin-resistant (that
is, MRSA) increased from 35.9% in 1992 to 64.4% in 2003
in ICUs in the United States [4]; however, more recent data
from nine metropolitan areas suggest that the incidence
rates have declined among patients with health-care–asso-
ciated, community-onset or hospital-onset infections [5].
Despite the variation in incidence, MRSA infections re-
main a significant public health problem. MRSA-associated
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pital stay [6-8]. The mean duration of hospitalization and
associated costs of MRSA infections have been reported to
be significantly higher than those of methicillin-susceptible
S. aureus (MSSA) infections [9,10]. The majority of this
cost difference can be attributed to excess hospitalization
rather than to charges for antibiotic use, radiologic proce-
dures or laboratory services.
Vancomycin and linezolid are the commonly recom-
mended agents in clinical guidelines for the treatment of
MRSA-related pneumonia [11,12]. In addition to these two
agents, telavancin is the only other agent approved for the
treatment of MRSA NP in the United States and Europe.
Two large, prospective, randomized, double-blind trials
demonstrated that linezolid (600 mg every 12 hours) was
statistically noninferior to fixed-dose vancomycin (1 g twice
daily) for the treatment of NP [13,14]. In a retrospective
combined subgroup analysis of these two trials, researchers
found significantly higher survival and clinical cure rates
with linezolid treatment compared with vancomycin treat-
ment [14]. Using post hoc data from the same studies, in-
vestigators have reported similar findings in patients with
MRSA ventilator-associated pneumonia [15].
In a recent prospective, randomized, double-blind, con-
trolled, multicenter study, specifically focused on MRSA-
confirmed NP, researchers found greater clinical efficacy
(defined as resolution of signs and symptoms, improved or
lack of progression in chest imaging and no additional anti-
bacterial treatment required) with linezolid than with
adjusted-dose vancomycin [16]. That study’s sample size
for the modified intent-to-treat population (MRSA-
confirmed population) was 224 patients in each arm,
with an end-of-study success rate of 57.6% for linezolid-
treated patients and 46.6% for vancomycin-treated pa-
tients (95% confidence interval (CI) for differences from
0.5 to 21.6; P = 0.042). Linezolid was noninferior and
statistically superior to vancomycin in end-of-treatment
clinical and in end-of-treatment and end-of-study mi-
crobiologic outcomes. All-cause 60-day mortality rates
were similar (15.7% for linezolid and 17.0% for vanco-
mycin), as were the serious adverse event (SAE) rates.
Despite its higher acquisition costs, the overall cost for
treating MRSA NP with linezolid may be lower because it
is associated with better clinical outcomes compared with
vancomycin. Yet, few researchers have investigated the
costs associated with MRSA NP [17] and, in particular, the
economic outcomes associated with treatments for MRSA
NP. In two cost-effectiveness analyses based on a retro-
spective decision-analytic modeling approach, investigators
found linezolid to be less costly and more efficacious than
vancomycin for patients with suspected MRSA NP [18,19].
However, these earlier modeling studies either did not ad-
dress the use of these agents in the US context [18] or were
focused only on first-line therapy [19].Our purpose in this economic analysis was to investigate
the economic impact of improved clinical outcomes with
linezolid compared with vancomycin in the treatment of
hospitalized patients with MRSA-confirmed NP in the
United States using a decision tree with a payer perspec-
tive and flexibility for real-world clinical conditions.
Methods
Model design
We conducted a cost-effectiveness analysis of intraven-
ous (IV) linezolid compared with IV vancomycin for the
treatment of MRSA NP in hospitalized adults, which
was based on a decision tree modeling approach. The
decision tree model was developed to capture first-line
and second-line therapy. Because of the short-term win-
dow for the clinical management of an NP episode, the
model time horizon was up to 4 weeks, which was vali-
dated by practicing physicians. This time horizon spans
periods typical for ICU and general ward stays during
first-line and second-line treatment [18,20,21]. A total
payer perspective (assuming a per diem basis of pay-
ment) was considered in the base case analysis, which
was comprehensive and comprised all inpatient and out-
patient health-care costs (antibiotic and medical). Be-
cause this was an economic model in which we used
only previously published data to create a hypothetical
patient pathway, ethical approval and informed consent
were neither applicable nor required.
The hypothetical model population was assumed to be
similar to the population included in a recent phase IV,
prospective, double-blind, controlled, multicenter,
international clinical trial of IV linezolid (600 mg every
12 hours) or IV vancomycin (15 mg/kg every 12 hours,
dose-adjusted based on trough levels and renal func-
tion) for the treatment of MRSA NP [16]. The full de-
tails of the characteristics and resource use for this
MRSA-confirmed trial population have been reported
previously [21,22] and include the following data:
mean age 62 years, 69% white, 66% male, 75% mechan-
ically ventilated, 87% had at least 1 day in the ICU and
63% were from the United States. The population used
for analysis in the model was hospitalized adult pa-
tients with a confirmed MRSA NP diagnosis.
Patients with suspected and/or confirmed Gram-positive
NP could initially be treated with empiric IV antibiotic
therapy (for example, vancomycin or linezolid in combi-
nation with ceftazidime, imipenem or piperacillin/tazobac-
tam) for up to 3 days while laboratory confirmation of NP
pathogen occurred (Figure 1). This empiric treatment
pathway was not included in the base case analysis. Fol-
lowing confirmation of MRSA NP, the economic model
analysis began and patients were placed on first-line treat-
ment (vancomycin or linezolid) for 10 days (Figure 1). We
focused on the component of treatment after MRSA
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recent clinical trial data available [16] and because this is
an important time point in clinical decision-making for re-
evaluation of the antibiotic treatment and coverage.
Possible treatment outcomes associated with first-line
therapy were (1) treatment success (defined as resolution
of signs and symptoms of NP, improvement or lack of
progression in chest imaging and no additional antibac-
terial treatment required among survivors), (2) failure
due to lack of efficacy among survivors, (3) drug dis-
continuation due to SAEs and (4) failure due to death
(Figure 1). A penalty, described in the section below,
was assigned for patients whose treatment failed due to
lack of efficacy or was discontinued due to SAEs.
Patients whose first-line treatment succeeded would fin-
ish their 10-day treatment duration and exit the model. In
cases of any failure of first-line treatment, patients were
switched to second-line treatment (for example, patients
whose first-line treatment with linezolid failed were
switched to second-line vancomycin, and vice versa) after
7 days, with the second-line treatment lasting 10 days.
The model did not include a third-line treatment, given
the lack of published data.
Model inputs, outcomes and assumptions
In the base case scenario, the model was based primarily
on recent MRSA NP clinical trial data [16] (Table 1). Li-
nezolid and vancomycin were the main treatment com-
parators. In the base case analysis, we used 10-day
treatment duration for the first- and second-line therap-
ies. Data on length of hospital stay, inpatient and out-
patient resource use and associated costs, and drug costsFigure 1 Decision model tree. NP, Nosocomial pneumonia; MRSA, Methiwere obtained by analysis of the recent clinical trial and
published literature (Tables 1 and 2) [16,21,23]. Key re-
sources included in the model were days of antibiotic
treatment, hospital general ward stay, hospital ICU stay,
mechanical ventilator use, days on IV therapy, inpatient
visits (to physician, attending and/or intensivist), in-
patient laboratory work and physician office visits.
In cases where a discontinuation due to an SAE or
treatment failure occurred, patients were assumed to
stay 1.7 or 2.0 additional days in the hospital, respect-
ively, during first-line treatment compared with patients
whose treatment was successful [18]. This additional
length of stay was determined on the basis of post hoc
analysis of recent clinical trial data [16,21,22] wherein
bivariate analysis was conducted to compare length of
stay in patients with or without moderate or severe ad-
verse events and in patients with first-line treatment
success versus failure. These values were further vali-
dated with expert opinion of the authors who reported
the pertinent studies.
This study is primarily a cost-effectiveness analysis and
not a cost–utility analysis, because the treatment effect
of interest is drug efficacy (that is, proportion of patients
successfully treated), instead of quality-adjusted life years
(QALYs) or life-years (LYs). The latter two outcomes
(QALYs and Lys) were not considered ideal for this ana-
lysis and hence are not reported, because the model uses
a short-term duration and the trial data used for this
model suggest equal mortality rates between linezolid
and vancomycin [16]. As a result, there were negligible
differences in QALYs and no differences in LYs between
the treatment arms.cillin-resistant Staphylococcus aureus; SAEs, Serious adverse events.






Efficacy and safety end pointsc,%
Efficacy (in survivors) 54.8 (49.8d to 66.7) 44.9 (35.5 to 52.9) β [16,20]
Mortalitye 27.2 27.2 –
SAEs leading to discontinuationf 1.8 (0d to 5.2) 3.1 (0d to 6.5) β [14,16]
Failure leading to discontinuationg 16.2 24.8 –
Resource use
Total days in hospitalh 17.9 (13.9d to 18.8) 18.6 (14.6d to 20.1) γ [20,21]
Days of treatmenti 10.0 (7 to 14) 10.0 (7 to 14) Uniform [16]
Days in ICUh 10.1 (6.1d to 12.2) 10.6 (6.6d to 16.2) γ [20,21]
Days on mechanical ventilationh 8.3 (4.3d to 10.4) 8.1 (4.1d to 14.3) γ [20,21]
Additional days in hospital due to SAE 1.7 (0 to 5)d 1.7 (0 to 5)d γ [21]
Additional days in hospital due to treatment failure 2 (0 to 5)d 2 (0 to 5)d Uniform Expert input
Number of days until switch to second-line after treatment failure/SAE
with first- line
7 (5 to 10)d 7 (5 to 10)d Uniform Expert input
Days receiving IV antibiotich 10.0 10.0 – [16]
Antibiotic IV doses/dayh 2.0 2.0 – Product label
Physician/attending/intensivist visit (inpatient)/dayi 1.0 1.0 – Expert input
Lab work/wki,j 7.0 8.0 – Expert input
aIV, Intravenous; SAE, Serious adverse event. Clinical response rate for modified intent-to-treat population at end-of-study time point was used [16,21,23]. bRanges and
distributions are provided for variables that were used in sensitivity analyses. cSame clinical data were used for second-line treatment. dThis was an arbitrary assumption
that was validated with expert opinion. eWeighted average, because model assumes equal mortality due to lack of significant mortality difference (linezolid = 63 of 224;
vancomycin = 59 of 224). fLinezolid = 4 of 224; vancomycin = 7 of 224. gBecause this is a decision tree model, this probability was derived as [1 – (probability of efficacy +
probability mortality + probability of SAEs leading to discontinuation)]. hData input for first line treatment only. iData input for first and second line treatment. jDaily serum
creatinine levels and complete blood count for both antibiotics and once-weekly serum vancomycin levels for vancomycin.
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reported in the Results section, are total costs and ef-
fectiveness proportion for the two treatments, total
cost per successfully treated patient for each treat-
ment (calculated as ratio of total costs and totalTable 2 Model input data on unit costs of medical care (in 20
Cost inputs Cos
Inpatient cost per day (general ward) $1,9
Inpatient cost per day (ICU) $3,4
Mechanical ventilation per day $22
Physician/attending/intensivist visit $17
Specialist inpatient visit $25
Laboratory test (serum creatinine levels) $65
Laboratory test (serum vancomycin levels) $36
Laboratory test (complete blood count) $34
Outpatient parenteral antibiotic therapy/day $20
Injection costs for administration $7.6
IV linezolid 600 mg $11
IV vancomycin 1 g $5.8
aCPT, Current procedural terminology; ID, Infectious disease; IV, Intravenous. All cos
Consumer Price Index [24-29]. bRanges are provided for variables that were used in
sensitivity analysis. cArbitrary ±25% range was used. dBased on testing once every day
week for only vancomycin.effectiveness) and incremental cost-effectiveness ratio
(ICER), calculated as the difference in costs between
treatments divided by the difference in the proportion
of successfully treated patients receiving linezolid ver-
sus vancomycin.12 US dollars)a
t base case value (rangeb) Source
73.7 ($1,480.3 to $2,467.1)c [24]
15.6 ($2,561.7 to $4,269.5)c [24]
5.2 ($168.9 to $281.5)c [25]
5.0 CPT 99233 [26]
1.2 CPT 99253 [26]
.9 CPT 80069d [26]
.3 CPT 80202e [26]
.3 CPT 85025d [26]
4.2 [27]
[28]
4.6 ($86.0 to $143.3)c [29]
($4.4 to $7.3)c [29]
ts were adjusted to US dollars using medical care component of the US
sensitivity analyses. γ-distribution was used for these variables for probabilistic
(while in hospital) for both linezolid and vancomycin. eBased on testing once a
Patel et al. Critical Care 2014, 18:R157 Page 5 of 9
http://ccforum.com/content/18/4/R157The following key assumptions were made in the
model:
 Every patient received treatment as long as they
were hospitalized, and all patients were on IV
therapy during their hospital stay.
 In the absence of published data for second-line treat-
ment, the clinical inputs for second-line treatment were
the same as those used for first-line treatment [18].
 Because we used the 60-day mortality rates reported
in the clinical trial [16], which represented total
mortality and included deaths associated with first-
line and second-line treatment, mortality occurred
only at the end of first-line treatment to avoid over-
estimation attributable to double-counting. Because
the first-line mortality rates did not statistically differ
between linezolid and vancomycin in the clinical trial,
these rates were considered the same in the model.
 There were no patient dropouts due to failure or
SAEs after first-line treatment.
 Patients whose second-line treatment failed and
those who had SAEs were deemed to have com-
pleted the duration of therapy because no third-line
therapy was available.
 Although the mean ICU stay was 10 days, ICU stay
was considered to be 7 days if treatment duration
was 7 days and the patient’s first-line treatment suc-
ceeded. Alternatively, if the treatment duration was
14 days, then the ICU stay would be 10 days and the
remaining 4 days would be in the general ward.
Sensitivity analyses
Univariate (one-way) sensitivity analysis was conducted to
assess the impact of model uncertainties and the robustness
of our analysis. Key model parameters were varied individu-
ally within the predefined sensitivity ranges (Tables 2 and
3), and ICERs were recorded. A published source was usedTable 3 Detailed cost results of the base case scenarioa
Cost items per patient Linezolid Vancomycin
Drug treatment $2,189 $746
Drug administration $172 $182
Inpatient drug cost $2,361 $928
ICU $34,217 $34,728
General ward $2,451 $3,524
Mechanical ventilation $1,869 $1,824
Physician/attending visit $1,970 $2,091
Lab work $1,137 $1,245
SAE/failure costs $2,162 $2,651
Inpatient medical cost $43,807 $46,064
Total costs $46,168 $46,992
aSAE, Serious adverse event.for ranges whenever possible. In the absence of strong pub-
lished data, an arbitrary range was used (such as ±4 days
for length of stay or ±25% for costs). The results are pre-
sented in the form of a tornado diagram, with the variables
stacked in decreasing order of impact on the ICER.
A probabilistic sensitivity analysis (PSA) was also per-
formed, wherein all parameters were varied simultaneously
within their range using 10,000 second-order Monte
Carlo simulations. γ-distribution was specified for re-




Under the model base case settings (with no empiric treat-
ment, a 10-day treatment duration, and discontinuation or
switch of therapy possible after 7 days), the total inpatient
(medical plus drug) costs were $46,168 for linezolid and
$46,992 for vancomycin (Table 3). Although the drug
costs were $1,433 higher with linezolid compared with
vancomycin, the medical costs associated with linezolid
were $2,256 lower with linezolid than with vancomycin.
Overall, treatment with linezolid was associated with
lower total costs (by a mean of $824) and greater effective-
ness (+2.7% absolute difference in proportion of success-
fully treated patients) compared with vancomycin. The
expected proportions of successfully treated patients were
62.9% and 60.2% for linezolid and vancomycin, respectively.
Factoring in these expected success rates, the total costs
per successfully treated patient were predicted to be
$73,420 (linezolid) and $78,073 (vancomycin), for a total
cost savings of $4,653. Thus, the ICER (in this case, incre-
mental cost per successfully treated patient) was in favor of
linezolid compared with vancomycin (that is, linezolid
dominated vancomycin), owing to linezolid’s lower total
costs and greater efficacy in successfully treating patients.
We calculated that, within the model, approximately
80% of the total treatment costs were attributable to hos-
pital stay, primarily ICU costs, because each patient stayed
at least 10 days (plus additional days if first-line therapy
failed) in the ICU and the cost per day of ICU stay in the
United States is very high. General ward costs were higher
with vancomycin compared with linezolid, because, even
though the length of stay in the hospital was comparable
between treatments, there was a higher percentage of pa-
tients for whom vancomycin failed as first-line therapy
and thus were transitioned to second-line treatment and
had an associated longer general ward stay. Moreover, the
higher percentage of vancomycin-treated patients requir-
ing second-line therapy may have led to marginally higher
costs for additional physician visits and laboratory work.
However, drug therapy, physician visits, laboratory tests
and SAEs and/or treatment failure each accounted for no
more than 5% of the total costs (Table 3).
-300,000 -200,000 -100,000 0 100,000 200,000 300,000
No. of days in Hospital ICU_VAN
Clinical efficacy_VAN
No. of days in Hospital ICU_LIN
Clinical efficacy_LIN
No. of days on MV_VAN
No. of days in Hospital Total_VAN
No. of days on MV_LIN
No. of days of treatment
No. of days in Hospital Total_LIN
Additional days in hospital due to tx failure
Days after which switch made to 2nd line due to failure/SAE
Inpatient cost per day (general ward)
Cost of Linezolid IV
Inpatient cost per day (ICU)
Additional days in hospital due to SAE
Cost of Vancomycin IV, 1gm
SAE leading to discontinuation_VAN
Cost for mechanical ventilation
SAE leading to discontinuation_LIN
Incremental Cost Effectiveness Ratio
Low
High
Figure 2 One-way sensitivity analyses of key parameters (Tornado diagram). IV, Intravenous; LIN, Linezolid; MV, Mechanical ventilation; SAE,
Serious adverse events; tx, Treatment; VAN, Vancomycin.
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The results of one-way sensitivity analysis (as seen in the
Tornado diagram in Figure 2) demonstrated variables
that had the greatest impact on the model results. The
ICERs ranged from a low of about − $240,000, when
ICU stay with linezolid was at its lower value of 6.1 (sug-
gesting a dominant scenario for linezolid), to a high of
around $210,000, when the clinical efficacy of vanco-
mycin was at its higher value of 52.9% and $160,000,
when ICU stay with vancomycin was at a low of 6.6 days.
(These ICERs can be considered greater than the accept-
able willingness-to-pay (WTP) threshold, making vanco-
mycin the cost-effective option.) There is no clearly
defined WTP threshold for successful treatment of one
patient, and hence different WTP values were tested in
the PSA cost-effectiveness acceptability curve.
A cost-effectiveness acceptability curve generated from
a PSA is presented in Figure 3. This plot displays the
percentages for linezolid being more cost-effective com-
pared to vancomycin at the different WTP thresholds.
Linezolid had a 64.4% likelihood of being cost-effective
at a WTP threshold of $0 and a 90.8% chance at a WTP
threshold of $120,000.Discussion
This economic decision tree analysis is the first, to our
knowledge, to mirror real-world clinical conditions by
allowing for a switch of therapy if needed (that is, it models
first- and second-line treatment) and allowed us to assess
the impact of varying treatment parameters, including
treatment duration. To our knowledge, no other published
studies of NP have researchers accounted for these factors
from a US health-care payer perspective. Our results with
this model show that linezolid is a cost-effective alternative
to vancomycin for the treatment of MRSA-confirmed NP,
owing primarily to the higher clinical response rate of
linezolid-treated patients compared with vancomycin-
treated patients. The higher acquisition cost of linezolid
was offset by lower costs of treatment failure and SAEs, as
well as fewer days spent in the hospital, when we accounted
for combined first-line and second-line therapies. Only dir-
ect medical costs were included in the model, with a dis-
tinction made between inpatient and outpatient costs. For
NP, inpatient costs accounted for the largest proportion of
overall costs.
Linezolid was a more cost-effective treatment option in












































Figure 3 Cost-effectiveness acceptability curve of linezolid versus vancomycin.
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and high vancomycin efficacy rate) and under varying
WTP thresholds in PSA. Length of ICU stay and clinical ef-
ficacy rate appeared to be the most sensitive variables in
one-way analysis, with the greatest impact on the ICER.
This was expected, especially with regard to the length of
ICU stay, because ICU stay per diem is very expensive in
the United States and the cost of ICU stay accounts for the
largest proportion of total treatment cost.
Our results are consistent with those reported in two
previous cost-effectiveness analyses in which investiga-
tors found therapy initiated with linezolid to be less
costly and more efficacious than vancomycin for patients
with suspected MRSA NP [18,19]. Mullins et al. applied
a retrospective decision-analytic model to pooled effi-
cacy data derived from two clinical trials and health plan
hospital claims and determined hospital costs for US
patients with suspected NP. When median daily hospital
charges and mean treatment durations were factored
in, total hospitalization charges were estimated to be
$32,636 for linezolid treatment compared with $32,024
for vancomycin treatment. The ICER for linezolid per
life saved was $3,600. However, they based their efficacy
estimates on a small sample of patients with MRSA NP
(N = 160) and examined the cost-effectiveness of only
first-line linezolid or vancomycin treatment.
In a German cost-effectiveness analysis [18], the re-
searchers used a decision-analytic model based on previ-
ously published clinical data [14] and found higher clinical
cure and survival rates with linezolid, but at a small incre-
mental cost compared with vancomycin, resulting in ac-
ceptable ICERs of cost per death avoided and cost per
patient cured [18]. From a clinical standpoint, they dem-
onstrated that linezolid had better efficacy than vanco-
mycin for the treatment of MRSA NP (on the basis of trial
data specifically in MRSA-confirmed patients), with fewerpatients requiring a switch to second-line therapy. The
longer hospital stays associated with switching from
vancomycin as first-line treatment to a second-line ther-
apy required additional resource use, including physicians’
and other health-care professionals’ time that could have
been spent treating other patients.
Our present economic analysis included patients who re-
ceived optional empiric therapy (2 days) followed by first-
and/or second-line treatment once MRSA was confirmed,
with the empiric treatment costs not included in the pre-
sented scenarios. Costs, therefore, were not considered in
patients who did not have MRSA infection. In clinical prac-
tice, initiation with empiric antibiotic treatment is started
as soon as MRSA is suspected, and antibiotic treatment
success and the related costs of empiric therapy are deter-
mined by how well MRSA is predicted and by the propor-
tion of patients with MRSA in the treated population. Our
present analysis therefore does not include the costs of ini-
tial empiric therapy and the harm that comes from (1) not
covering MSSA by using only MRSA coverage, (2) choosing
vancomycin and the possibility of renal toxicity developing
in a patient without MRSA and (3) not starting empiric
therapy with either drug and having a delay in starting ap-
propriate therapy until after culture results have been con-
firmed. Although we did not address these clinical aspects
in our model, they are relevant and important and should
be explored in future studies.
Vancomycin and linezolid are the most commonly rec-
ommended and prescribed treatment options for MRSA
NP [11,12]. Vancomycin has been the mainstay generic
for decades; however, challenges with tissue penetration
at the site of infection, therapeutic drug monitoring and
increased risk for renal dysfunction in NP patients
makes the use of this agent more difficult in critically ill
patients. In the economic analysis presented here, we
used the recent and only clinical trial data specifically
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patients with MRSA NP [16]. To date, linezolid is the
only agent to have proven better clinical success rates in
NP than vancomycin in a MRSA-only population. Linez-
olid is sold as ZYVOX and is under patent in the United
States until the end of 2014; thus, use of this agent may
increase further with the introduction of generic ver-
sions. However, there is another oxazolidinone drug for
nosocomial pneumonia currently under development,
tedizolid, in ongoing phase III trials. A newer glycopep-
tide, telavancin, became available in late 2013 for gram
positive NP, and while the phase III trials included
MRSA patients, the studies were not specifically de-
signed to examine clinical success in the MRSA-only
population. Thus, the only MRSA-specific NP study to
date is the Wunderink et al. study [16], on which our
economic analysis is based.
Our study has limitations. In the model’s base case
scenario, we considered the conditions under which the
Wunderink clinical trial was performed [16], which may
differ in real-life US clinical practice. Further, because
the Wunderink trial enrolled US patients, the results
may not be applicable to scenarios outside the United
States. The model included only first-line and second-
line treatments, not potential later treatment options.
However, this is consistent with other published models
[18] and is justifiable because the majority of the re-
sources used and outcomes witnessed were within the
first two lines of therapy. In the model, we estimated dir-
ect costs only and did not include indirect costs related
to lost productivity incurred as a result of the length of
hospital stay, convalescence or early mortality.
We used 60-day mortality data, calculated as a weighted
average of the 60-day mortality rates for the modified
intent-to-treat population in the clinical trial [16], which
were the best available “proxy” data for this 4-week model,
given that the difference between 30 and 60 days was
found to be small based on the survival curve derived
from the study. In addition, mortality rates were not statis-
tically different in the clinical trial; thus, a cost per LY
saved calculation was less relevant, given that the trial was
never designed to show a difference in mortality. In fact,
patients could have received up to 2 days of vancomycin
before being randomized to the study drugs; thus, patients
doing poorly on vancomycin would have been less likely
to be enrolled in the study, where the chance of being ran-
domized to vancomycin was 50–50. Instead of focusing on
LYs, we used “proportion of successfully treated patients”
instead of QALYs as the efficacy measure in this model,
which could be considered a drawback, especially because
there is no clearly defined ICER threshold per successfully
treated patient. However, we think that successful treat-
ment is a clinically important efficacy measure for NP, and
hence it can be argued to be relevant for this model.Conclusion
Our US health-care system economic model using recent
MRSA-specific clinical trial data shows that treatment with
linezolid is less costly and more efficacious than treatment
with vancomycin for MRSA-confirmed NP. Cost savings
with linezolid were derived largely from lower treatment
failure rates, fewer days of hospitalization and lower inci-
dence of renal failure. We found our findings to be consist-
ent in sensitivity analyses. In future analyses, researchers
should use other country costs and resource-use data to
test result generalizability and could model the empiric
treatment phase before MRSA confirmation.
Key messages
 Linezolid is likely to be a cost-effective alternative
compared to vancomycin for the treatment of
MRSA NP, primarily owing to the former’s better
clinical success rate.
 Higher drug costs for linezolid are offset by lower
overall medical costs due to fewer treatment failures
and fewer serious adverse events, such as renal
failure, as well as fewer days spent in the hospital,
when accounting for combined first-line and
second-line therapies.
 For MRSA NP, inpatient costs accounted for the
largest proportion of overall costs.
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